Literature DB >> 18237829

Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.

Peter A Newman1, Andrea Daley, Roberta Halpenny, Mona Loutfy.   

Abstract

Sustained recruitment over time of tens of thousands of clinical trial volunteers is essential to the development of safe and efficacious HIV vaccines. This study explored, in depth, reasons for declining to enroll among persons screened in as eligible for a Phase IIb prophylactic HIV vaccine trial. Thirteen non-enrollees completed a self-administered questionnaire; of those, 11 completed a 1-h follow-up interview. Interviews were transcribed verbatim and themes derived using narrative thematic analysis and NVivo software. Concerns about negative social consequences of false HIV-positive tests, trial uncertainties, side effects, double-blind assignment, trial duration, uncertain efficacy, behavioral disinhibition and stigma emerged as reasons for declining to enroll. Social, psychological and emotional dimensions of HIV vaccine trial participation--including false-positives and anticipated stigma and discrimination, possible impact on intimate relationships, and concerns about behavioral disinhibition--suggest that provision of voluntary trial-related psychosocial counseling, a trial ombudsperson, alternate trial sites, and systematic community engagement in trial planning, recruitment and evaluation may facilitate informed participation in safe and ethically conducted HIV vaccine trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237829     DOI: 10.1016/j.vaccine.2007.12.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

2.  Immune to addiction: the ethical dimensions of vaccines against substance abuse.

Authors:  Michael J Young; Dominic A Sisti; Hila Rimon-Greenspan; Jason L Schwartz; Arthur L Caplan
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

3.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

4.  A Demographic Analysis of Racial/Ethnic Minority Enrollment Into HVTN Preventive Early Phase HIV Vaccine Clinical Trials Conducted in the United States, 2002-2016.

Authors:  Katherine Foy Huamani; Barbara Metch; Gail Broder; Michele Andrasik
Journal:  Public Health Rep       Date:  2018-12-05       Impact factor: 2.792

5.  Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.

Authors:  Sung-Jae Lee; Peter A Newman; Naihua Duan; William E Cunningham
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

6.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

7.  Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs.

Authors:  Sasha Uhlmann; Michael John Milloy; Keith Ahamad; Paul Nguyen; Thomas Kerr; Evan Wood; Lindsey Richardson
Journal:  Am J Addict       Date:  2015-03-24

8.  Bridging the divide: HIV prevention research and Black men who have sex with men.

Authors:  Michele Peake Andrasik; Christian Chandler; Borris Powell; Damon Humes; Steven Wakefield; Katharine Kripke; Daniel Eckstein
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

9.  Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).

Authors:  Peter A Newman; Sung-Jae Lee; Naihua Duan; Ellen Rudy; Terry K Nakazono; John Boscardin; Lisa Kakinami; Steven Shoptaw; Allison Diamant; William E Cunningham
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

10.  Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.

Authors:  Marci D Cottingham; Julianne M Kalbaugh; Teresa Swezey; Jill A Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.